UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-19291 CorVel Corporation (Exact name of registrant as specified in its charter) Delaware 33-0282651 ( State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to x Commission file number 0-19291 CORVEL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 33-0282651 (State or other jurisdict ...

CorVel Corporation (NASDAQ:CRVL) Q3 2022 Earnings Conference Call February 1, 2022 11:30 AM ET Company Participants Michael Combs - President and Chief Executive Officer Brandon O'Brien - Chief Financial Officer Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designe ...

PART I - FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents CorVel Corporation's unaudited consolidated financial statements for the periods ended September 30, 2021, detailing balance sheets, income statements, equity, and cash flows, which reflect significant year-over-year growth in revenues and net income [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of September 30, 2021, total assets slightly increased to $424.9 million from $424.8 million at March 31, 2021, with cash decreasing to $131.1 million while accounts receivable rose, and total liabilities slightly decreased as stockholders' equity grew to $223.8 million Consolidated Balance Sheet Highlights (Unaudited) | Account | Sep 30, 2021 ($) | Mar 31, 2021 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | $131.1M | $139.7M | | Accounts receivable, net | $69.4M | $64.7M | | Total current assets | $272.0M | $268.9M | | TOTAL ASSETS | $424.9M | $424.8M | | Total current liabilities | $162.6M | $162.5M | | Total liabilities | $201.1M | $204.4M | | Total stockholders' equity | $223.8M | $220.4M | [Consolidated Income Statements](index=5&type=section&id=Consolidated%20Income%20Statements) The company reported strong year-over-year growth, with three-month revenues increasing 16.0% to $157.7 million and net income rising 35.5% to $16.1 million, while six-month revenues grew 16.8% to $310.4 million and net income increased 63.2% to $32.9 million Three Months Ended September 30 (Unaudited) | Metric | 2021 ($) | 2020 ($) | Change | | :--- | :--- | :--- | :--- | | Revenues | $157.7M | $136.0M | +16.0% | | Gross Profit | $36.7M | $30.5M | +20.2% | | Net Income | $16.1M | $11.9M | +35.5% | | Diluted EPS | $0.88 | $0.65 | +35.4% | Six Months Ended September 30 (Unaudited) | Metric | 2021 ($) | 2020 ($) | Change | | :--- | :--- | :--- | :--- | | Revenues | $310.4M | $265.6M | +16.8% | | Gross Profit | $73.9M | $57.0M | +29.6% | | Net Income | $32.9M | $20.2M | +63.2% | | Diluted EPS | $1.81 | $1.11 | +63.1% | [Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Consolidated%20Statements%20of%20Stockholders%27%20Equity) For the six months ended September 30, 2021, total stockholders' equity increased from $220.4 million to $223.8 million, driven by $32.9 million in net income, partially offset by $39.8 million in treasury stock purchases, with stock-based compensation also contributing - During the six months ended September 30, 2021, the company repurchased **284,348 shares** of treasury stock for **$39.8 million**[14](index=14&type=chunk) - Net income of **$32.9 million** for the six-month period increased retained earnings[14](index=14&type=chunk) [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended September 30, 2021, net cash provided by operating activities was $35.2 million, a decrease from the prior year, while net cash used in investing activities increased to $11.6 million and financing activities rose significantly to $32.2 million due to increased treasury stock repurchases Six Months Ended September 30 (Unaudited) | Cash Flow Activity | 2021 ($) | 2020 ($) | | :--- | :--- | :--- | | Net cash provided by operating activities | $35.2M | $39.5M | | Net cash used in investing activities | ($11.6M) | ($6.9M) | | Net cash used in financing activities | ($32.2M) | ($9.7M) | | (Decrease)/increase in cash | ($8.6M) | $22.9M | | Cash at end of period | $131.1M | $106.1M | [Notes to Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail the company's accounting policies, including revenue recognition disaggregated into Patient Management and Network Solutions services, stock-based compensation, treasury stock repurchases, and lease accounting, noting a reduction in lease footprint due to remote work - The company operates in a single reportable segment, managed care, with two service lines: Patient Management and Network Solutions[29](index=29&type=chunk) Revenue by Service Line (Three Months Ended Sep 30) | Service Line | 2021 ($) | 2020 ($) | | :--- | :--- | :--- | | Patient management services | $104.7M | $90.3M | | Network solutions services | $53.1M | $45.8M | | **Total services** | **$157.7M** | **$136.0M** | - In May 2021, the Board of Directors approved a **1 million share** expansion to the stock repurchase program, and during the six months ended Sep 30, 2021, the company repurchased **284,348 shares** for **$39.8 million**[58](index=58&type=chunk) - Due to the COVID-19 pandemic and an expected increase in remote work, the company no longer believes it is reasonably certain to exercise most of its lease renewal options, leading to a reduction in the right-of-use asset and lease liability[71](index=71&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the financial results, highlighting a 16.0% revenue increase for the quarter ended September 30, 2021, driven by economic recovery from the COVID-19 pandemic, with both Patient Management and Network Solutions services showing significant growth and strong liquidity supported by cash from operations despite increased stock repurchases [Overview and Business Segments](index=22&type=section&id=Overview%20and%20Business%20Segments) CorVel provides nationwide medical cost containment and managed care services for workers' compensation, auto insurance, and group health benefits, operating as a single reportable segment aggregated from geographically managed regions, with two service lines: Patient Management and Network Solutions - The company is a nationwide provider of medical cost containment and managed care services for workers' compensation, auto insurance, and group health[80](index=80&type=chunk) - CorVel operates in one reportable operating segment, managed care, which is aggregated from its geographically managed regions[85](index=85&type=chunk)[87](index=87&type=chunk) [COVID-19 Pandemic Impact](index=23&type=section&id=COVID-19%20Pandemic%20Impact) The COVID-19 pandemic significantly impacted the business in 2020, leading to a **10%** headcount reduction and cuts in discretionary spending, with the company deferring **$10.4 million** in payroll taxes under the CARES Act, while sequential revenue increases through September 2021 indicate recovery - The company implemented a **10%** headcount reduction in early 2020 and reduced discretionary spending in response to the pandemic[90](index=90&type=chunk) - The company deferred **$10.4 million** in payroll taxes under the CARES Act, with repayments scheduled for late 2021 and 2022[114](index=114&type=chunk) - Sequential revenue increases were realized through the September 2021 quarter, indicating a recovery trend[90](index=90&type=chunk) [Results of Operations - Three Months Ended Sep 30, 2021 vs 2020](index=25&type=section&id=Results%20of%20Operations%20-%20Three%20Months%20Ended%20Sep%2030%2C%202021%20vs%202020) For the third quarter of 2021, revenues grew **16.0%** to **$157.7 million**, driven by increases in Patient Management and Network Solutions services, leading to a **20.2%** rise in gross profit and a **35.5%** increase in net income to **$16.1 million**, with diluted EPS rising to **$0.88** Q3 2021 vs Q3 2020 Performance | Metric | Q3 2021 ($) | Q3 2020 ($) | Change | | :--- | :--- | :--- | :--- | | Revenue | $157.7M | $136.0M | +16.0% | | Gross Profit | $36.7M | $30.5M | +20.2% | | Net Income | $16.1M | $11.9M | +35.5% | | Diluted EPS | $0.88 | $0.65 | +35.4% | - Revenue growth was driven by higher revenue from TPA and related services, with total new claims increasing by **16%** YoY[101](index=101&type=chunk) - Cost of revenues increased **14.7%**, primarily due to a **12%** increase in headcount in field operations to support revenue growth[103](index=103&type=chunk) [Results of Operations - Six Months Ended Sep 30, 2021 vs 2020](index=28&type=section&id=Results%20of%20Operations%20-%20Six%20Months%20Ended%20Sep%2030%2C%202021%20vs%202020) For the first six months of fiscal 2022, revenues increased **16.8%** to **$310.4 million**, with Patient Management and Network Solutions both growing, leading to a gross profit margin improvement from **21.5%** to **23.8%**, and net income surging **63.2%** to **$32.9 million**, with diluted EPS increasing to **$1.81** H1 2021 vs H1 2020 Performance | Metric | H1 2021 ($) | H1 2020 ($) | Change | | :--- | :--- | :--- | :--- | | Revenue | $310.4M | $265.6M | +16.8% | | Gross Profit | $73.9M | $57.0M | +29.6% | | Net Income | $32.9M | $20.2M | +63.2% | | Diluted EPS | $1.81 | $1.11 | +63.1% | - Total new claims increased by **18%** during the six-month period compared to the prior year[110](index=110&type=chunk) - The effective tax rate for the six-month period was **18.9%** in 2021, down from **22.3%** in 2020, primarily due to the impact of stock option exercises[113](index=113&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains a strong liquidity position with **$131.1 million** in cash as of September 30, 2021, funding operations primarily through **$35.2 million** in cash flow from operations, despite increased capital expenditures of **$11.6 million** and significant share repurchases of **$39.8 million** - Cash decreased by **$8.6 million** to **$131.1 million** as of Sep 30, 2021, from March 31, 2021, primarily due to increased spending on share repurchases[114](index=114&type=chunk) - Net cash used in financing activities increased by **$22.5 million** YoY to **$32.2 million**, mainly due to spending **$39.8 million** on share repurchases compared to **$14.4 million** in the prior year period[122](index=122&type=chunk) - Net cash from operating activities decreased by **$4.3 million** YoY to **$35.2 million**, partly because a prior year deferral of payroll taxes under the CARES Act was not available in 2021[120](index=120&type=chunk) [Critical Accounting Policies](index=32&type=section&id=Critical%20Accounting%20Policies) The company states that its significant accounting policies, requiring management's judgment and estimates, are described in its Annual Report on Form 10-K for the fiscal year ended March 31, 2021, with no changes made since that filing - No changes in critical accounting policies have been made since the filing of the Annual Report on Form 10-K for the fiscal year ended March 31, 2021[129](index=129&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As of September 30, 2021, the company had no market risk sensitive instruments, did not use derivative financial instruments, and had no outstanding debt, resulting in negligible exposure to market risk - The Company held no market risk sensitive instruments for trading purposes and had no debt outstanding as of September 30, 2021[131](index=131&type=chunk) [Controls and Procedures](index=32&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of September 30, 2021, with no material changes in internal control over financial reporting during the quarter - The CEO and CFO concluded that as of September 30, 2021, the company's disclosure controls and procedures were effective[132](index=132&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[134](index=134&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=34&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in litigation arising in the ordinary course of business, which management believes will not have a material impact on its consolidated financial position or results of operations - Management believes that ongoing litigation will not result in any payment that would be material to the company's financial position or operations[136](index=136&type=chunk) [Risk Factors](index=34&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks to the company's business, including the ongoing impact of the COVID-19 pandemic, intense competition, potential declines in workers' compensation claims, reliance on technology, cybersecurity threats, potential litigation, evolving government regulations, and common stock volatility [Risks Related to Our Business and Our Industry](index=34&type=section&id=Risks%20Related%20to%20Our%20Business%20and%20Our%20Industry) The company faces risks from the COVID-19 pandemic's economic disruption, intense competition from national providers and in-house services, and potential adverse effects from a decline in workers' compensation claims, failure to grow market share, or inability to retain key personnel - The COVID-19 pandemic could materially adversely affect business operations and financial results due to factors like reduced economic activity, lower claim volumes, and potential customer financial instability[139](index=139&type=chunk)[140](index=140&type=chunk) - The company faces significant competition from other managed care companies, PPOs, and insurance carriers that may perform similar services in-house[150](index=150&type=chunk)[157](index=157&type=chunk) - A long-term decline in work-related injuries and workers' compensation claims would have a material adverse impact on the business[152](index=152&type=chunk) [Risks Related to Cybersecurity and Our Information Systems](index=38&type=section&id=Risks%20Related%20to%20Cybersecurity%20and%20Our%20Information%20Systems) The business is highly dependent on IT systems and sensitive data, making it vulnerable to cybersecurity attacks that could lead to data loss, reputational damage, litigation, and financial harm, despite continuous security investments, as threats are sophisticated and evolving - A cybersecurity attack could result in the unauthorized disclosure of customer or company information, disrupting operations and causing significant reputational and financial harm[168](index=168&type=chunk) - The frequency and sophistication of cyber-attacks are increasing, and despite security investments, there is no assurance that breaches can be prevented[169](index=169&type=chunk)[171](index=171&type=chunk) - An interruption in the ability to access critical data could cause customers to cancel service and have a material adverse effect on business operations[177](index=177&type=chunk) [Risks Related to Potential Litigation](index=41&type=section&id=Risks%20Related%20to%20Potential%20Litigation) The company faces litigation risk from its utilization management services, potentially leading to claims for adverse medical outcomes, and is also exposed to lawsuits challenging cost containment programs, alongside rising liability insurance costs - The company is exposed to claims for adverse medical consequences arising from its recommendations concerning medical treatment plans[181](index=181&type=chunk) - Healthcare providers have brought individual and class action lawsuits challenging the company's cost containment programs, which could result in significant liabilities if successful[183](index=183&type=chunk) [Risks Related to Our Regulatory Environment](index=42&type=section&id=Risks%20Related%20to%20Our%20Regulatory%20Environment) The business is subject to numerous evolving state and federal regulations, including licensing and data privacy laws like GDPR and CCPA, which could increase operational costs, reduce demand for services, or expose the company to increased liability - Changes in government regulations, including licensing requirements and standards for medical review, could increase costs and impact competitiveness[187](index=187&type=chunk) - Increasingly stringent data privacy laws, such as GDPR and CCPA, could impact business models and expose the company to increased liability and reputational harm[190](index=190&type=chunk) [Risks Related to Ownership of Our Common Stock](index=42&type=section&id=Risks%20Related%20to%20Ownership%20of%20Our%20Common%20Stock) The market price of the company's common stock may be highly volatile, and the ongoing stock repurchase program, while intended to enhance long-term value, could increase price volatility and diminish cash reserves, with no guarantee of effectiveness or price stability - The market price and trading volume of the company's common stock may be volatile, leading to potential substantial losses for stockholders[191](index=191&type=chunk) - The stock repurchase program could increase stock price volatility and will diminish cash reserves, which could impact the ability to pursue future strategic opportunities[192](index=192&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the company's stock repurchase activity for the quarter ended September 30, 2021, where **165,455 shares** were repurchased at an average price of **$154.46** per share, with **1,062,100 shares** remaining authorized under the expanded program Common Stock Repurchases (Quarter Ended Sep 30, 2021) | Period | Total Shares Purchased | Average Price Paid Per Share ($) | | :--- | :--- | :--- | | July 2021 | 61,175 | $137.25 | | August 2021 | 56,537 | $155.59 | | September 2021 | 47,743 | $175.17 | | **Total** | **165,455** | **$154.46** | - In May 2021, the Board of Directors increased the total number of shares authorized for repurchase to **38,000,000**, and as of September 30, 2021, **1,062,100 shares** may yet be purchased under the program[196](index=196&type=chunk) [Defaults Upon Senior Securities](index=44&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[197](index=197&type=chunk) [Mine Safety Disclosures](index=44&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[198](index=198&type=chunk) [Other Information](index=44&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this period - None[199](index=199&type=chunk) [Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the company's certificate of incorporation, bylaws, employee stock purchase plan, and certifications by the CEO and CFO as required by the Sarbanes-Oxley Act - Exhibits include corporate governance documents, employee benefit plans, and required CEO/CFO certifications (Sections 302 and 906)[201](index=201&type=chunk)[202](index=202&type=chunk)[203](index=203&type=chunk)[204](index=204&type=chunk)

CorVel Corporation (NASDAQ:CRVL) Q2 2021 Earnings Conference Call November 2, 2021 11:30 AM ET Company Participants Michael Combs - President and Chief Executive Officer Brandon O'Brien - Chief Financial Officer Conference Call Participants Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-19291 CORVEL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 33-0282651 (State or other jurisdiction of ...

CorVel Corporation (NASDAQ:CRVL) Q1 2021 Earnings Conference Call May 27, 2021 11:30 AM ET Company Participants Michael Combs - President and CEO Brandon O'Brien - CFO Conference Call Participants Operator Thank you for standing by. Welcome to the CorVel Corporation Quarterly Earnings Release Webcast. During the course of this webcast, CorVel Corporation may make projections or other forward-looking statements regarding future events or the future financial performances of the company. CorVel wishes to caut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | |--------------------------------------------------------------------------------------------------------------|------------------------------------- ...

Revenue Performance - The Company's revenues decreased to $141.5 million in the quarter ended December 31, 2020, down from $148.1 million in the same quarter of 2019, a decrease of $6.6 million, or 4.4%[92] - Revenues decreased to $141.5 million for the quarter ended December 31, 2020, down from $148.1 million for the same quarter in 2019, a decrease of 4.4%[101] - Revenues for the nine months ended December 31, 2020 decreased to $407.1 million, down from $445.2 million, a decrease of 8.6%[111] - Patient management services revenues decreased to $96.6 million, down 1.8%, while network solutions services revenues decreased to $45.0 million, down 9.7%[101] Cost Management - Cost of revenues decreased to $110.6 million in the quarter ended December 31, 2020, from $118.8 million in the same quarter of 2019, a decrease of $8.2 million, or 6.9%[93] - Cost of revenues decreased to $110.6 million for the quarter ended December 31, 2020, down from $118.8 million, a decrease of 6.9%[103] - Cost of revenues for the nine months ended December 31, 2020 decreased to $319.2 million, down from $350.0 million, a decrease of 8.8%[112] - General and administrative expenses decreased to $16.9 million in the quarter ended December 31, 2020, from $17.0 million in the same quarter of 2019, a decrease of $0.1 million, or 0.4%[94] - General and administrative expenses decreased to $16.9 million for the quarter ended December 31, 2020, down from $17.0 million, a decrease of 0.4%[106] Profitability - Income before income tax provision increased to $14.0 million in the quarter ended December 31, 2020, from $12.3 million in the same quarter of 2019, an increase of $1.7 million, or 13.9%[95] - Income before income tax provision increased to $14.0 million for the quarter ended December 31, 2020, up from $12.3 million, an increase of 13.9%[107] - Net income for the quarter ended December 31, 2020, was $11.4 million, compared to $9.4 million in the same quarter of 2019, an increase of $2.0 million, or 21.7%[100] - Diluted earnings per share increased to $0.63 in the quarter ended December 31, 2020, from $0.50 in the same quarter of 2019, an increase of $0.13 per share, or 26.0%[97] Cash Flow and Liquidity - Net cash provided by operating activities increased to $73.8 million for the nine months ended December 31, 2020, up from $66.3 million, an increase of 11.3%[121] - Cash and cash equivalents increased to $128.8 million as of December 31, 2020, up from $83.2 million as of March 31, 2020, an increase of 54.8%[115] - Net cash flow used in financing activities decreased to $14.9 million for the nine months ended December 31, 2020, from $40.6 million for the same period in 2019, a decrease of $25.7 million[123] - Spending on share repurchases decreased to $22.1 million for the nine months ended December 31, 2020, down from $47.5 million for the same period in 2019[123] Tax and Effective Rate - The effective tax rate for the quarter ended December 31, 2020, was 18.5%, compared to 23.7% in the same quarter of 2019[95] - The effective tax rate decreased to 18.5% for the quarter ended December 31, 2020, compared to 23.7% for the same quarter in 2019[107] Operational Changes - The Company implemented a 10% reduction in headcount during the pandemic, which contributed to a decrease in salaries and overall operational costs[88] Financial Position and Risks - Total contractual obligations as of December 31, 2020, amounted to $92,235,000, with $4,218,000 due within one year[124] - Operating and finance leases total $89,725,000, with $3,603,000 due within one year[124] - The company does not believe that inflation-related pricing pressures are material to its revenues or net income[127] - As of December 31, 2020, the company held no market risk sensitive instruments for trading purposes and had no debt outstanding[133] - The company is involved in litigation arising in the ordinary course of business, but management believes it will not result in material payments[126] - No changes in critical accounting policies have been made since the last Annual Report on Form 10-K[131] - The company does not have off-balance sheet arrangements that would materially impact its financial position[128] - Management is not currently aware of any reasonably likely events that would result in materially different amounts being reported[131]

CorVel Corporation (NASDAQ:CRVL) Q4 2020 Earnings Conference Call February 2, 2021 11:30 AM ET Company Participants Michael Combs – President and Chief Executive Officer Brandon O’Brien – Chief Financial Officer Conference Call Participants Operator Thank you for standing by. Welcome to the CorVel Corporation Quarterly Earnings Release Webcast. During the course of this webcast, CorVel Corporation may make projections or other forward-looking statements regarding future events or the future financial perfor ...